Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > FDA applications ???

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon May 02, 2022 12:43pm

125 Views

Post# 34647962

RE:RE:FDA applications ???

Doccole wrote: Glad to see this gone.

it would be nice to have some news that would end this death spiral. I mean, I continue to pick up shares. Im about double what I wanted to be at....which is great, because I'll be in decent shape when they have a reverse split haha!

good news today, even though the market doesn't care.

Market won't care as they don't know how to read it.
It's only a psychological barrier for future Institutional Investors.
All barriers out of the way accept valuation.

Now - all eyes on 346 - that's the key to everything. How big is 346?

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Cannabis Report – Nov. 15, 2024